Protalix BioTherapeutics Rating Reiterated by JPMorgan Chase & Co. (PLX)
Protalix BioTherapeutics (NYSE:PLX)‘s stock had its “overweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, Analyst RN reports. They currently have a $7.00 target price on the stock, down from their previous target price of $8.00. JPMorgan Chase & Co.’s price target would suggest a potential upside of 84.70% from the company’s current price.
Shares of Protalix BioTherapeutics (NYSE:PLX) traded up 2.90% on Tuesday, hitting $3.90. The stock had a trading volume of 65,365 shares. Protalix BioTherapeutics has a 1-year low of $3.70 and a 1-year high of $5.72. The stock’s 50-day moving average is $4.31 and its 200-day moving average is $4.39. The company’s market cap is $361.5 million.
Protalix BioTherapeutics (NYSE:PLX) last released its earnings data on Thursday, March 13th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.02) by $0.10. On average, analysts predict that Protalix BioTherapeutics will post $-0.03 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday. They now have a $4.25 price target on the stock, down previously from $5.50. Analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.